PL3894411T3 - Pochodne 7-fenoksy-N-(3-azabicyklo[3.2.1]oktan-8-ylo)-6,7-dihydro-5H-pirolo[1,2-b][1,2,4]triazolo-2-aminy i związki pokrewne jako modulatory gamma-sekretazy do leczenia choroby Alzheimera - Google Patents

Pochodne 7-fenoksy-N-(3-azabicyklo[3.2.1]oktan-8-ylo)-6,7-dihydro-5H-pirolo[1,2-b][1,2,4]triazolo-2-aminy i związki pokrewne jako modulatory gamma-sekretazy do leczenia choroby Alzheimera

Info

Publication number
PL3894411T3
PL3894411T3 PL19824250.5T PL19824250T PL3894411T3 PL 3894411 T3 PL3894411 T3 PL 3894411T3 PL 19824250 T PL19824250 T PL 19824250T PL 3894411 T3 PL3894411 T3 PL 3894411T3
Authority
PL
Poland
Prior art keywords
octan
azabicyclo
pyrrolo
triazole
alzheimer
Prior art date
Application number
PL19824250.5T
Other languages
English (en)
Inventor
Beat Frei
Hasane Ratni
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3894411T3 publication Critical patent/PL3894411T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL19824250.5T 2018-12-13 2019-12-11 Pochodne 7-fenoksy-N-(3-azabicyklo[3.2.1]oktan-8-ylo)-6,7-dihydro-5H-pirolo[1,2-b][1,2,4]triazolo-2-aminy i związki pokrewne jako modulatory gamma-sekretazy do leczenia choroby Alzheimera PL3894411T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18212199 2018-12-13
PCT/EP2019/084538 WO2020120521A1 (en) 2018-12-13 2019-12-11 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
PL3894411T3 true PL3894411T3 (pl) 2024-10-07

Family

ID=64665266

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19824250.5T PL3894411T3 (pl) 2018-12-13 2019-12-11 Pochodne 7-fenoksy-N-(3-azabicyklo[3.2.1]oktan-8-ylo)-6,7-dihydro-5H-pirolo[1,2-b][1,2,4]triazolo-2-aminy i związki pokrewne jako modulatory gamma-sekretazy do leczenia choroby Alzheimera

Country Status (32)

Country Link
US (2) US12195470B2 (pl)
EP (2) EP3894411B1 (pl)
JP (2) JP7566745B2 (pl)
KR (1) KR102910810B1 (pl)
CN (2) CN117946116A (pl)
AR (1) AR116906A1 (pl)
AU (1) AU2019395774B2 (pl)
BR (1) BR112021009443A2 (pl)
CA (1) CA3117870A1 (pl)
CL (1) CL2021001547A1 (pl)
CO (1) CO2021006837A2 (pl)
CR (1) CR20210305A (pl)
DK (1) DK3894411T3 (pl)
ES (1) ES2986688T3 (pl)
FI (1) FI3894411T3 (pl)
HR (1) HRP20241097T1 (pl)
HU (1) HUE067669T2 (pl)
IL (2) IL310081A (pl)
LT (1) LT3894411T (pl)
MA (1) MA54447B1 (pl)
MX (1) MX2021006761A (pl)
MY (1) MY208077A (pl)
PE (1) PE20211776A1 (pl)
PH (1) PH12021551387A1 (pl)
PL (1) PL3894411T3 (pl)
PT (1) PT3894411T (pl)
RS (1) RS65821B1 (pl)
SG (1) SG11202103340PA (pl)
SI (1) SI3894411T1 (pl)
TW (1) TWI831892B (pl)
UA (1) UA129650C2 (pl)
WO (1) WO2020120521A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019395774B2 (en) * 2018-12-13 2024-12-12 F. Hoffmann-La Roche Ag 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of Alzheimer's disease
AU2019412747B8 (en) 2018-12-27 2025-04-24 F. Hoffmann-La Roche Ag Process for the preparation exo-tert-butyl N-(3-azabicyclo[3.2.1]octan-8-yl)carbamate
AU2024312554A1 (en) 2023-06-19 2025-12-18 F. Hoffmann-La Roche Ag Process for the preparation of a chiral pyrrolo triazole alcohol
WO2025228863A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative
WO2026061922A1 (en) 2024-09-17 2026-03-26 F. Hoffmann-La Roche Ag Deuterated bicyclic heteroaryl derivatives
WO2026074067A1 (en) 2024-10-04 2026-04-09 F. Hoffmann-La Roche Ag Solid forms of a gamma-secretase modulator
WO2026146201A1 (en) 2025-01-03 2026-07-09 AlzeCure Pharma AB New compounds and uses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994349A (en) 1997-10-27 1999-11-30 Howard University 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives
CN1217918C (zh) 1998-04-01 2005-09-07 卡迪欧梅制药公司 氨基环己基醚化合物和其用途
WO2000047547A2 (en) 1999-02-12 2000-08-17 Nortran Pharmaceuticals Inc. Cycloalkyl amine compounds and uses thereof
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6448246B1 (en) 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands
AU775102B2 (en) 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7499263B2 (en) 2005-08-30 2009-03-03 Doosan Infracore Co., Ltd. Mobile power source cable connection system and method
WO2007032009A2 (en) 2005-09-15 2007-03-22 Biomas Ltd. Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis
CN101675045B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
ATE543799T1 (de) 2007-10-19 2012-02-15 Janssen Pharmaceutica Nv Piperidinyl- und piperazinylmodulatoren von g- sekretase
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ
RU2515976C2 (ru) 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
WO2010138901A1 (en) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
KR20120046327A (ko) 2009-09-04 2012-05-09 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 혼합된-금속-원자가 화합물에 기초한 멤리스터
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
CN103874702B (zh) 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
WO2014060112A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
WO2017042114A1 (en) 2015-09-09 2017-03-16 F. Hoffmann-La Roche Ag Bridged piperidine derivatives
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
CN109311878B (zh) * 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3535266B1 (en) * 2016-11-01 2021-12-29 F. Hoffmann-La Roche AG Bicyclic heteroaryl derivatives
US11319314B2 (en) * 2016-11-08 2022-05-03 Hoffmann-La Roche Inc. Phenoxytriazoles
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
US11370802B2 (en) 2018-01-22 2022-06-28 Hoffmann-La Roche, Inc. Triazolo-azepine derivatives
AU2019395774B2 (en) * 2018-12-13 2024-12-12 F. Hoffmann-La Roche Ag 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
IL283823B1 (en) 2024-03-01
US20220056036A1 (en) 2022-02-24
HRP20241097T1 (hr) 2024-11-08
BR112021009443A2 (pt) 2021-08-17
CN117946116A (zh) 2024-04-30
UA129650C2 (uk) 2025-06-25
DK3894411T3 (da) 2024-08-19
MY208077A (en) 2025-04-13
EP4424370A3 (en) 2024-12-25
SG11202103340PA (en) 2021-04-29
JP2025000919A (ja) 2025-01-07
ES2986688T3 (es) 2024-11-12
EP3894411B1 (en) 2024-06-19
TW202039499A (zh) 2020-11-01
EP4424370A2 (en) 2024-09-04
WO2020120521A1 (en) 2020-06-18
LT3894411T (lt) 2024-08-26
CR20210305A (es) 2021-07-20
IL310081A (en) 2024-03-01
FI3894411T3 (fi) 2024-08-15
IL283823A (en) 2021-07-29
RS65821B1 (sr) 2024-09-30
MA54447B1 (fr) 2024-08-30
CO2021006837A2 (es) 2021-06-10
CN113179641B (zh) 2024-01-02
JP7566745B2 (ja) 2024-10-15
CL2021001547A1 (es) 2021-12-24
US12195470B2 (en) 2025-01-14
PT3894411T (pt) 2024-08-08
AU2019395774B2 (en) 2024-12-12
KR20210102900A (ko) 2021-08-20
PE20211776A1 (es) 2021-09-08
EP3894411A1 (en) 2021-10-20
HUE067669T2 (hu) 2024-11-28
AU2019395774A1 (en) 2021-04-08
MA54447A (fr) 2022-03-23
CA3117870A1 (en) 2020-06-18
SI3894411T1 (sl) 2024-10-30
TWI831892B (zh) 2024-02-11
JP2022513466A (ja) 2022-02-08
IL283823B2 (en) 2024-07-01
KR102910810B1 (ko) 2026-01-12
CN113179641A (zh) 2021-07-27
MX2021006761A (es) 2021-07-15
PH12021551387A1 (en) 2022-05-16
US20250326758A1 (en) 2025-10-23
AR116906A1 (es) 2021-06-23

Similar Documents

Publication Publication Date Title
SI3894411T1 (sl) Derivati 7-fenoksi-N-(3-azabiciklo(3.2.1)oktan-8-il)-6,7-dihidro-5H- pirolo(1,2-b)(1,2,4)triazol-2-amina in sorodne spojine kot modulatorji gama-sekretaze za zdravljenje Alzheimerjeve bolezni
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
IL251285B (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
EA201791239A8 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
CL2016002836A1 (es) Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame).
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
EP3307738A4 (en) ARYL-DIHYDRO-2H-BENZO [B] [1,4] OXAZINE-SULPHONAMIDE AND RELATED COMPOUNDS FOR USE AS AGENTS OF RORY AND FOR THE TREATMENT OF DISEASES
IL275781A (en) Background 1,3,4,5-Tetrahydro-2H-pyrido[4,3-B]indole for the treatment, mitigation or prevention of disorders associated with TAU aggregates such as Alzheimer's disease
WO2015173633A3 (en) Hdl therapy markers
AU2017261291A1 (en) Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
BR112016007016A8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica
EP3292119A4 (en) DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
EP3709998B8 (en) N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer
EA201892638A1 (ru) Специфический аналог трифторэтилхинолина для применения при лечении apids
PL3737684T3 (pl) Pochodne 2,4,6,7-tetrahydropirazolo[4,3-d]pirymidyn-5-onu i związki pokrewne jako modulatory receptorów c5a do leczenia zapalenia naczyń i chorób zapalnych
MX2024007059A (es) Composicion que comprende un anticuerpo de protofibrilla anti-abeta y un inhibidor de beta-secretasa bace1 para el tratamiento de enfermedad de alzheimer.
IL267801B1 (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
HUE065093T2 (hu) 1,4-dihidrobenzo[D]pirazolo[3,4-F][1,3]diazepin származékok és kapcsolódó vegyületek, mint LRRK2, NUAK1 és/vagy TYK2 kináz modulátorok pl. autoimmun betegségek kezelésére
MX2017009597A (es) Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100.
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
LT3759113T (lt) 10-(di(fenil)metil)-4-hidroksi-8,9,9a,10-tetrahidro-7h-pirolo[1',2':4,5] pirazino[1,2-b]piridazin-3,5-diono dariniai ir susiję junginiai kaip ortomiksoviruso replikacijos inhibitoriai, skirti gripo gydymui
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
PL3597648T3 (pl) METODA WYTWARZANIA 3,6-DIPODSTAWIONEJ POCHODNEJ IMIDAZO[1, 2-b]PIRYDAZYNY